BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 19913804)

  • 1. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
    Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
    J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
    Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
    Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
    Bernstein EJ; Schmidt-Lauber C; Kay J
    Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
    Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
    Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
    Larson KN; Gagnon AL; Darling MD; Patterson JW; Cropley TG
    JAMA Dermatol; 2015 Oct; 151(10):1117-20. PubMed ID: 26017458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nephrogenic fibrosing dermatosis: From clinic to microscopy].
    Yoldez H; Ahlem B; Abderrahim E; Faten Z; Soumaya R
    Nephrol Ther; 2018 Feb; 14(1):47-49. PubMed ID: 29239786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathomechanisms of nephrogenic systemic fibrosis: new insights.
    Gupta A; Shamseddin MK; Khaira A
    Clin Exp Dermatol; 2011 Oct; 36(7):763-8. PubMed ID: 21790732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis: a review of the new conundrum.
    Goenka AH; Das CJ; Sharma R
    Natl Med J India; 2009; 22(6):302-6. PubMed ID: 20384019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
    Heverhagen JT; Krombach GA; Gizewski E
    Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis: concepts and perspectives.
    Igreja AC; Mesquita Kde C; Cowper SE; Costa IM
    An Bras Dermatol; 2012; 87(4):597-607. PubMed ID: 22892775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy.
    Foss C; Smith JK; Ortiz L; Hanevold C; Davis L
    Pediatr Dermatol; 2009; 26(5):579-82. PubMed ID: 19840315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: a concise review for cardiologists.
    Cheong BY; Muthupillai R
    Tex Heart Inst J; 2010; 37(5):508-15. PubMed ID: 20978560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis: clinical picture and treatment.
    Marckmann P; Skov L
    Radiol Clin North Am; 2009 Sep; 47(5):833-40, vi. PubMed ID: 19744598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk.
    Nicholas BA; Vricella GJ; Smith M; Passalacqua M; Gulani V; Ponsky LE
    Can J Urol; 2012 Feb; 19(1):6074-80. PubMed ID: 22316507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
    Varela CU; Prieto-Rayo JC
    Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis: is gadolinium to be blamed?
    Jikki PN
    J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.